Cross Country Healthcare Announces Second Quarter 2020 Financial Results
SELECTED FINANCIAL INFORMATION: |
||||||||||||
|
|
|
Variance |
Variance |
||||||||
|
|
|
Q2 2020 vs |
Q2 2020 vs |
||||||||
Dollars are in thousands, except per share amounts |
Q2 2020 |
Q2 2019 |
Q1 2020 |
|||||||||
Revenue |
$ |
216,779 |
|
|
7 |
|
% |
3 |
|
% |
||
Gross profit margin* |
23.4 |
|
% |
(200 |
) |
bps |
(20 |
) |
bps |
|||
Net loss attributable to common shareholders |
$ |
(14,151 |
) |
|
73 |
|
% |
(577 |
) |
% |
||
Diluted EPS |
$ |
(0.39 |
) |
|
$ |
1.05 |
|
|
$ |
(0.33 |
) |
|
Adjusted EBITDA* |
$ |
11,612 |
|
|
84 |
|
% |
152 |
|
% |
||
Adjusted EPS* |
$ |
0.16 |
|
|
$ |
0.15 |
|
|
$ |
0.17 |
|
|
Cash flows provided by operations |
$ |
16,569 |
|
|
34 |
|
% |
(3 |
) |
% |
* Refer to accompanying tables and discussion of Non-GAAP financial measures below.
“Our second quarter results reflect Cross Country’s position as a leader in the market, as well as strong execution in filling an unprecedented level of demand from clients responding to COVID-19,” said
Second quarter consolidated revenue was
The three and six months ended
For the six months ended
Quarterly Business Segment Highlights
Nurse and
Revenue from Nurse and
Revenue from
Search
Revenue from Search was
Cash Flow and Balance Sheet Highlights
Cash flow generated from operations for the quarter was
On
Outlook for Third Quarter 2020
The guidance below applies to management’s expectations for the third quarter of 2020.
|
Q3 2020 Range |
|
Year-over-Year |
|
Sequential |
Change |
|
Change |
|||
|
|
|
|
|
|
Revenue |
|
|
(19)% - (14)% |
|
(22)% - (17)% |
|
|
|
|
|
|
Gross Profit Margin |
23.8% - 24.3% |
|
(60) bps - (10) bps |
|
40 bps - 90 bps |
|
|
|
|
|
|
Adjusted EBITDA |
|
|
(45)% - (17)% |
|
(66)% - (48)% |
|
|
|
|
|
|
Adjusted EPS |
|
|
|
|
|
The Company continues to assess the impacts from COVID-19 on its operations, which were significant in the second quarter, and are expected to continue into the third quarter. As a result of the volatility and uncertainty from the pandemic, the Company has decided to widen the guidance ranges for the third quarter. Though the Company does not provide full year guidance, management expects to see sequential improvement in Revenue and Adjusted EBITDA for the fourth quarter, given the most recent trend in demand.
The above estimates are based on current management expectations and, as such, are forward-looking and actual results may differ materially. The above ranges do not include the potential impact of any future divestitures, mergers, acquisitions or other business combinations, changes in debt structure, or future share repurchases. The guidance also reflects the impacts from certain cost actions the Company has identified, and actual results may differ depending on timing and further actions it may take. See accompanying Non-GAAP financial measures and tables below.
INVITATION TO CONFERENCE CALL
The Company will hold its quarterly conference call on
ABOUT
Copies of this and other news releases as well as additional information about
NON-GAAP FINANCIAL MEASURES
This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with
FORWARD LOOKING STATEMENT
In addition to historical information, this press release contains statements relating to our future results (including certain projections and business trends) that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and are subject to the "safe harbor" created by those sections. Forward-looking statements consist of statements that are predictive in nature, depend upon or refer to future events. Words such as "expects", "anticipates", "intends", "plans", "believes", "estimates", "suggests", "appears", "seeks", "will", and "could", and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results and performance to be materially different from any future results or performance expressed or implied by these forward-looking statements. These factors include, but are not limited to, the following: the potential impacts of the COVID-19 pandemic on our business, financial condition, and results of operations, our ability to attract and retain qualified nurses, physicians and other healthcare personnel, costs and availability of short-term housing for our travel healthcare professionals, demand for the healthcare services we provide, both nationally and in the regions in which we operate, the functioning of our information systems, the effect of cyber security risks and cyber incidents on our business, the effect of existing or future government regulation and federal and state legislative and enforcement initiatives on our business, our clients’ ability to pay us for our services, our ability to successfully implement our acquisition and development strategies, including our ability to successfully integrate acquired businesses and realize synergies from such acquisitions, the effect of liabilities and other claims asserted against us, the effect of competition in the markets we serve, our ability to successfully defend the Company, its subsidiaries, and its officers and directors on the merits of any lawsuit or determine its potential liability, if any, and other factors set forth in Item 1A. "Risk Factors" in the Company’s Annual Report on Form 10-K for the year ended
Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this press release. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements. All references to "we", "us", "our", or "Cross Country" in this press release mean
|
|||||||||||||||||||
Consolidated Statements of Operations |
|||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) |
|||||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
2020 |
2019 |
2020 |
2020 |
2019 |
||||||||||||||
|
|
|
|
||||||||||||||||
Revenue from services |
$ |
216,779 |
|
$ |
202,757 |
|
$ |
210,064 |
|
$ |
426,843 |
|
$ |
397,928 |
|
||||
Operating expenses: |
|
|
|
|
|
||||||||||||||
Direct operating expenses |
166,045 |
|
151,169 |
|
160,461 |
|
326,506 |
|
298,086 |
|
|||||||||
Selling, general and administrative expenses |
42,254 |
|
45,944 |
|
45,881 |
|
88,135 |
|
91,980 |
|
|||||||||
Bad debt expense |
898 |
|
645 |
|
539 |
|
1,437 |
|
915 |
|
|||||||||
Depreciation and amortization |
3,929 |
|
3,557 |
|
3,296 |
|
7,225 |
|
6,541 |
|
|||||||||
Acquisition and integration-related costs |
— |
|
299 |
|
77 |
|
77 |
|
811 |
|
|||||||||
Restructuring costs |
2,330 |
|
137 |
|
564 |
|
2,894 |
|
1,277 |
|
|||||||||
Legal settlement charges |
— |
|
1,600 |
|
— |
|
— |
|
1,600 |
|
|||||||||
Impairment charges |
15,011 |
|
14,502 |
|
— |
|
15,011 |
|
14,502 |
|
|||||||||
Total operating expenses |
230,467 |
|
217,853 |
|
210,818 |
|
441,285 |
|
415,712 |
|
|||||||||
Loss from operations |
(13,688 |
) |
(15,096 |
) |
(754 |
) |
(14,442 |
) |
(17,784 |
) |
|||||||||
Other expenses (income): |
|
|
|
|
|
||||||||||||||
Interest expense |
744 |
|
1,438 |
|
867 |
|
1,611 |
|
2,860 |
|
|||||||||
Loss on early extinguishment of debt |
— |
|
54 |
|
— |
|
— |
|
414 |
|
|||||||||
Other income, net |
(5 |
) |
(76 |
) |
(31 |
) |
(36 |
) |
(158 |
) |
|||||||||
Loss before income taxes |
(14,427 |
) |
(16,512 |
) |
(1,590 |
) |
(16,017 |
) |
(20,900 |
) |
|||||||||
Income tax (benefit) expense |
(379 |
) |
34,758 |
|
178 |
|
(201 |
) |
31,746 |
|
|||||||||
Consolidated net loss |
(14,048 |
) |
(51,270 |
) |
(1,768 |
) |
(15,816 |
) |
(52,646 |
) |
|||||||||
Less: Net income attributable to noncontrolling interest in subsidiary |
103 |
|
404 |
|
321 |
|
424 |
|
795 |
|
|||||||||
Net loss attributable to common shareholders |
$ |
(14,151 |
) |
$ |
(51,674 |
) |
$ |
(2,089 |
) |
$ |
(16,240 |
) |
$ |
(53,441 |
) |
||||
|
|
|
|
|
|
||||||||||||||
Net loss per share attributable to common shareholders - Basic and Diluted |
$ |
(0.39 |
) |
$ |
(1.44 |
) |
$ |
(0.06 |
) |
$ |
(0.45 |
) |
$ |
(1.49 |
) |
||||
|
|
|
|
|
|
||||||||||||||
Weighted average common shares outstanding: |
|
|
|
|
|
||||||||||||||
Basic and Diluted |
36,123 |
|
35,824 |
|
35,873 |
|
35,998 |
|
35,763 |
|
|||||||||
|
|
|
|
|
|
|
|||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures |
|||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) |
|||||||||||||||||||
|
|||||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
2020 |
2019 |
2020 |
2020 |
2019 |
||||||||||||||
Adjusted EBITDA: (a) |
|
|
|
|
|
||||||||||||||
Net loss attributable to common shareholders |
$ |
(14,151 |
) |
$ |
(51,674 |
) |
$ |
(2,089 |
) |
$ |
(16,240 |
) |
$ |
(53,441 |
) |
||||
Interest expense |
744 |
|
1,438 |
|
867 |
|
1,611 |
|
2,860 |
|
|||||||||
Income tax (benefit) expense |
(379 |
) |
34,758 |
|
178 |
|
(201 |
) |
31,746 |
|
|||||||||
Depreciation and amortization |
3,929 |
|
3,557 |
|
3,296 |
|
7,225 |
|
6,541 |
|
|||||||||
Acquisition and integration-related costs (b) |
— |
|
299 |
|
77 |
|
77 |
|
811 |
|
|||||||||
Restructuring costs (c) |
2,330 |
|
137 |
|
564 |
|
2,894 |
|
1,277 |
|
|||||||||
Legal settlements and fees (d) |
1,561 |
|
1,600 |
|
— |
|
1,561 |
|
1,600 |
|
|||||||||
Impairment charges (e) |
15,011 |
|
14,502 |
|
— |
|
15,011 |
|
14,502 |
|
|||||||||
Loss on early extinguishment of debt (f) |
— |
|
54 |
|
— |
|
— |
|
414 |
|
|||||||||
Other income, net |
(5 |
) |
(76 |
) |
(31 |
) |
(36 |
) |
(158 |
) |
|||||||||
Equity compensation |
2,072 |
|
1,004 |
|
927 |
|
2,999 |
|
1,535 |
|
|||||||||
Applicant tracking system costs (g) |
397 |
|
315 |
|
502 |
|
899 |
|
1,449 |
|
|||||||||
Net income attributable to noncontrolling interest in subsidiary |
103 |
|
404 |
|
321 |
|
424 |
|
795 |
|
|||||||||
Adjusted EBITDA (a) |
$ |
11,612 |
|
$ |
6,318 |
|
$ |
4,612 |
|
$ |
16,224 |
|
$ |
9,931 |
|
||||
|
|
|
|
|
|
||||||||||||||
Adjusted EPS: (h) |
|
|
|
|
|
||||||||||||||
Numerator: |
|
|
|
|
|
||||||||||||||
Net loss attributable to common shareholders |
$ |
(14,151 |
) |
$ |
(51,674 |
) |
$ |
(2,089 |
) |
$ |
(16,240 |
) |
$ |
(53,441 |
) |
||||
Non-GAAP adjustments - pretax: |
|
|
|
|
|
||||||||||||||
Acquisition and integration-related costs (b) |
— |
|
299 |
|
77 |
|
77 |
|
811 |
|
|||||||||
Restructuring costs (c) |
2,330 |
|
137 |
|
564 |
|
2,894 |
|
1,277 |
|
|||||||||
Legal settlements and fees (d) |
1,561 |
|
1,600 |
|
— |
|
1,561 |
|
1,600 |
|
|||||||||
Impairment charges (excluding rebranding impacts) (e) |
15,011 |
|
— |
|
— |
|
15,011 |
|
— |
|
|||||||||
Rebranding impairments and accelerated amortization (e) |
1,406 |
|
15,106 |
|
731 |
|
2,137 |
|
15,106 |
|
|||||||||
Loss on early extinguishment of debt (f) |
— |
|
54 |
|
— |
|
— |
|
414 |
|
|||||||||
Applicant tracking system costs (g) |
397 |
|
315 |
|
502 |
|
899 |
|
1,449 |
|
|||||||||
Nonrecurring income tax adjustments |
313 |
|
35,675 |
|
— |
|
313 |
|
35,675 |
|
|||||||||
Tax impact of non-GAAP adjustments |
(958 |
) |
(1,151 |
) |
(12 |
) |
(970 |
) |
(1,985 |
) |
|||||||||
Adjusted net income (loss) attributable to common shareholders - non-GAAP |
$ |
5,909 |
|
$ |
361 |
|
$ |
(227 |
) |
$ |
5,682 |
|
$ |
906 |
|
||||
|
|
|
|
|
|
||||||||||||||
Denominator: |
|
|
|
|
|
||||||||||||||
Weighted average common shares - basic, GAAP |
36,123 |
|
35,824 |
|
35,873 |
|
35,998 |
|
35,763 |
|
|||||||||
Dilutive impact of share-based payments (i) |
76 |
|
117 |
|
455 |
|
265 |
|
107 |
|
|||||||||
Adjusted weighted average common shares - diluted, non-GAAP |
36,199 |
|
35,941 |
|
36,328 |
|
36,263 |
|
35,870 |
|
|||||||||
|
|
|
|
|
|
||||||||||||||
Reconciliation: |
|
|
|
|
|
||||||||||||||
Diluted EPS, GAAP |
$ |
(0.39 |
) |
$ |
(1.44 |
) |
$ |
(0.06 |
) |
$ |
(0.45 |
) |
$ |
(1.49 |
) |
||||
Non-GAAP adjustments - pretax: |
|
|
|
|
|
||||||||||||||
Acquisition and integration-related costs (b) |
— |
|
0.01 |
|
— |
|
— |
|
0.03 |
|
|||||||||
Restructuring costs (c) |
0.06 |
|
— |
|
0.02 |
|
0.08 |
|
0.03 |
|
|||||||||
Legal settlements and fees (d) |
0.04 |
|
0.05 |
|
— |
|
0.04 |
|
0.05 |
|
|||||||||
Impairment charges (excluding rebranding impacts) (e) |
0.42 |
|
— |
|
— |
|
0.42 |
|
— |
|
|||||||||
Rebranding impairments and accelerated amortization (e) |
0.04 |
|
0.42 |
|
0.02 |
|
0.06 |
|
0.42 |
|
|||||||||
Loss on early extinguishment of debt (f) |
— |
|
— |
|
— |
|
— |
|
0.01 |
|
|||||||||
Applicant tracking system costs (g) |
0.01 |
|
0.01 |
|
0.01 |
|
0.02 |
|
0.04 |
|
|||||||||
Nonrecurring income tax adjustments |
0.01 |
|
0.99 |
|
— |
|
0.01 |
|
0.99 |
|
|||||||||
Tax impact of non-GAAP adjustments |
(0.03 |
) |
(0.03 |
) |
— |
|
(0.03 |
) |
(0.05 |
) |
|||||||||
Adjusted EPS, non-GAAP (h) |
$ |
0.16 |
|
$ |
0.01 |
|
$ |
(0.01 |
) |
$ |
0.15 |
|
$ |
0.03 |
|
||||
|
|||||||
Consolidated Balance Sheets |
|||||||
(Unaudited, amounts in thousands) |
|||||||
|
|||||||
|
|
|
|||||
|
2020 |
2019 |
|||||
|
|
|
|||||
Assets |
|
|
|||||
Current assets: |
|
|
|||||
Cash and cash equivalents |
$ |
6,234 |
|
$ |
1,032 |
|
|
Accounts receivable, net |
156,104 |
|
169,528 |
|
|||
Prepaid expenses |
5,275 |
|
6,097 |
|
|||
Insurance recovery receivable |
4,954 |
|
5,011 |
|
|||
Other current assets |
1,985 |
|
1,689 |
|
|||
Total current assets |
174,552 |
|
183,357 |
|
|||
Property and equipment, net |
11,960 |
|
11,832 |
|
|||
Operating lease right-of-use assets |
11,553 |
|
16,964 |
|
|||
|
90,924 |
|
101,066 |
|
|||
Trade names, indefinite-lived |
5,900 |
|
5,900 |
|
|||
Other intangible assets, net |
39,001 |
|
44,957 |
|
|||
Other non-current assets |
18,311 |
|
18,298 |
|
|||
Total assets |
$ |
352,201 |
|
$ |
382,374 |
|
|
|
|
|
|||||
Liabilities and Stockholders' Equity |
|
|
|||||
Current liabilities: |
|
|
|||||
Accounts payable and accrued expenses |
$ |
54,183 |
|
$ |
45,726 |
|
|
Accrued employee compensation and benefits |
36,274 |
|
31,307 |
|
|||
Operating lease liabilities - current |
4,883 |
|
4,878 |
|
|||
Other current liabilities |
3,441 |
|
3,554 |
|
|||
Total current liabilities |
98,781 |
|
85,465 |
|
|||
Revolving credit facility |
49,101 |
|
70,974 |
|
|||
Operating lease liabilities - non-current |
16,757 |
|
19,070 |
|
|||
Non-current deferred tax liabilities |
6,860 |
|
7,523 |
|
|||
Long-term accrued claims |
25,042 |
|
26,938 |
|
|||
Contingent consideration |
— |
|
4,867 |
|
|||
Other long-term liabilities |
6,586 |
|
4,037 |
|
|||
Total liabilities |
203,127 |
|
218,874 |
|
|||
|
|
|
|||||
Commitments and contingencies |
|
|
|||||
|
|
|
|||||
Stockholders' equity: |
|
|
|||||
Common stock |
4 |
|
4 |
|
|||
Additional paid-in capital |
307,985 |
|
305,643 |
|
|||
Accumulated other comprehensive loss |
(1,327 |
) |
(1,240 |
) |
|||
Accumulated deficit |
(158,015 |
) |
(141,775 |
) |
|||
|
148,647 |
|
162,632 |
|
|||
Noncontrolling interest in subsidiary |
427 |
|
868 |
|
|||
Total stockholders' equity |
149,074 |
|
163,500 |
|
|||
Total liabilities and stockholders' equity |
$ |
352,201 |
|
$ |
382,374 |
|
|
|
|||||||||||||||||||||||
Segment Data (j) |
|||||||||||||||||||||||
(Unaudited, amounts in thousands) |
|||||||||||||||||||||||
|
|||||||||||||||||||||||
|
Three Months Ended |
|
Year-over-Year |
|
Sequential |
||||||||||||||||||
|
|
% of |
|
|
% of |
|
|
% of |
|
% change |
|
% change |
|||||||||||
|
2020 |
Total |
|
2019 |
Total |
|
2020 |
Total |
|
Fav (Unfav) |
|
Fav (Unfav) |
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Revenue from services: |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Nurse and |
$ |
198,098 |
|
91 |
% |
|
$ |
180,787 |
|
89 |
% |
|
$ |
188,233 |
|
89 |
% |
|
10 |
% |
|
5 |
% |
|
16,872 |
|
8 |
% |
|
18,028 |
|
9 |
% |
|
18,181 |
|
9 |
% |
|
(6 |
)% |
|
(7 |
)% |
|||
Search |
1,809 |
|
1 |
% |
|
3,942 |
|
2 |
% |
|
3,650 |
|
2 |
% |
|
(54 |
)% |
|
(50 |
)% |
|||
|
$ |
216,779 |
|
100 |
% |
|
$ |
202,757 |
|
100 |
% |
|
$ |
210,064 |
|
100 |
% |
|
7 |
% |
|
3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Contribution income (loss): (k) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Nurse and |
$ |
20,638 |
|
|
|
$ |
16,111 |
|
|
|
$ |
14,157 |
|
|
|
28 |
% |
|
46 |
% |
|||
|
1,219 |
|
|
|
508 |
|
|
|
631 |
|
|
|
140 |
% |
|
93 |
% |
||||||
Search |
(1,051 |
) |
|
|
(181 |
) |
|
|
(335 |
) |
|
|
(481 |
)% |
|
(214 |
)% |
||||||
|
20,806 |
|
|
|
16,438 |
|
|
|
14,453 |
|
|
|
27 |
% |
|
44 |
% |
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Corporate overhead (l) |
13,224 |
|
|
|
11,439 |
|
|
|
11,270 |
|
|
|
(16 |
)% |
|
(17 |
)% |
||||||
Depreciation and amortization |
3,929 |
|
|
|
3,557 |
|
|
|
3,296 |
|
|
|
(10 |
)% |
|
(19 |
)% |
||||||
Acquisition and integration-related costs (b) |
— |
|
|
|
299 |
|
|
|
77 |
|
|
|
100 |
% |
|
100 |
% |
||||||
Restructuring costs (c) |
2,330 |
|
|
|
137 |
|
|
|
564 |
|
|
|
NM |
|
|
(313 |
)% |
||||||
Legal settlement charges (d) |
— |
|
|
|
1,600 |
|
|
|
— |
|
|
|
100 |
% |
|
— |
% |
||||||
Impairment charges (e) |
15,011 |
|
|
|
14,502 |
|
|
|
— |
|
|
|
(4 |
)% |
|
(100 |
)% |
||||||
Loss from operations |
$ |
(13,688 |
) |
|
|
$ |
(15,096 |
) |
|
|
$ |
(754 |
) |
|
|
9 |
% |
|
NM |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Six Months Ended |
|
|
|
Year-over-Year |
|
|
||||||||||||||||
|
|
% of |
|
|
% of |
|
|
|
% change |
|
|
||||||||||||
|
2020 |
Total |
|
2019 |
Total |
|
|
Fav (Unfav) |
|
|
|||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Revenue from services: |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Nurse and |
$ |
386,331 |
|
91 |
% |
|
$ |
356,424 |
|
89 |
% |
|
|
|
|
8 |
% |
|
|
||||
|
35,053 |
|
8 |
% |
|
34,187 |
|
9 |
% |
|
|
|
|
3 |
% |
|
|
||||||
Search |
5,459 |
|
1 |
% |
|
7,317 |
|
2 |
% |
|
|
|
|
(25 |
)% |
|
|
||||||
|
$ |
426,843 |
|
100 |
% |
|
$ |
397,928 |
|
100 |
% |
|
|
|
|
7 |
% |
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Contribution income (loss): (k) |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Nurse and |
$ |
34,795 |
|
|
|
$ |
30,407 |
|
|
|
|
|
|
14 |
% |
|
|
||||||
|
1,850 |
|
|
|
913 |
|
|
|
|
|
|
103 |
% |
|
|
||||||||
Search |
(1,386 |
) |
|
|
(604 |
) |
|
|
|
|
|
(129 |
)% |
|
|
||||||||
|
35,259 |
|
|
|
30,716 |
|
|
|
|
|
|
15 |
% |
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Corporate overhead (l) |
24,494 |
|
|
|
23,769 |
|
|
|
|
|
|
(3 |
)% |
|
|
||||||||
Depreciation and amortization |
7,225 |
|
|
|
6,541 |
|
|
|
|
|
|
(10 |
)% |
|
|
||||||||
Acquisition and integration-related costs (b) |
77 |
|
|
|
811 |
|
|
|
|
|
|
91 |
% |
|
|
||||||||
Restructuring costs (c) |
2,894 |
|
|
|
1,277 |
|
|
|
|
|
|
(127 |
)% |
|
|
||||||||
Legal settlement charges (d) |
— |
|
|
|
1,600 |
|
|
|
|
|
|
100 |
% |
|
|
||||||||
Impairment charges (e) |
15,011 |
|
|
|
14,502 |
|
|
|
|
|
|
(4 |
)% |
|
|
||||||||
Loss from operations |
$ |
(14,442 |
) |
|
|
$ |
(17,784 |
) |
|
|
|
|
|
19 |
% |
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
NM-Not meaningful. |
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|||||||||||||||||||
Summary Condensed Consolidated Statements of Cash Flows |
|||||||||||||||||||
(Unaudited, amounts in thousands) |
|||||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
2020 |
2019 |
2020 |
2020 |
2019 |
||||||||||||||
|
|
|
|
|
|
||||||||||||||
Net cash provided by operating activities |
$ |
16,569 |
|
$ |
12,355 |
|
$ |
17,162 |
|
$ |
33,731 |
|
$ |
25,142 |
|
||||
Cash used in investing activities |
(1,528 |
) |
(429 |
) |
(962 |
) |
(2,490 |
) |
(1,674 |
) |
|||||||||
Net cash used in financing activities |
(21,402 |
) |
(5,383 |
) |
(4,599 |
) |
(26,001 |
) |
(14,678 |
) |
|||||||||
Effect of exchange rate changes on cash |
(4 |
) |
1 |
|
(34 |
) |
(38 |
) |
21 |
|
|||||||||
Change in cash and cash equivalents |
(6,365 |
) |
6,544 |
|
11,567 |
|
5,202 |
|
8,811 |
|
|||||||||
Cash and cash equivalents at beginning of period |
12,599 |
|
18,286 |
|
1,032 |
|
1,032 |
|
16,019 |
|
|||||||||
Cash and cash equivalents at end of period |
$ |
6,234 |
|
$ |
24,830 |
|
$ |
12,599 |
|
$ |
6,234 |
|
$ |
24,830 |
|
||||
|
|
|
|
|
|
|
|||||||||||||||||||
Other Financial Data |
|||||||||||||||||||
(Unaudited) |
|||||||||||||||||||
|
|||||||||||||||||||
|
Three Months Ended |
Six Months Ended |
|||||||||||||||||
|
|
|
|
|
|
||||||||||||||
|
2020 |
2019 |
2020 |
2020 |
2019 |
||||||||||||||
|
|
|
|
|
|
||||||||||||||
Consolidated gross profit margin (m) |
23.4 |
% |
25.4 |
% |
23.6 |
% |
23.5 |
% |
25.1 |
% |
|||||||||
|
|
|
|
|
|
||||||||||||||
Nurse and |
|
|
|
|
|
||||||||||||||
FTEs (n) |
5,801 |
|
7,016 |
|
7,145 |
|
6,473 |
|
7,016 |
|
|||||||||
Average Nurse and |
$ |
375 |
|
$ |
283 |
|
$ |
290 |
|
$ |
328 |
|
$ |
281 |
|
||||
|
|
|
|
|
|
||||||||||||||
|
|
|
|
|
|
||||||||||||||
Days filled (p) |
9,195 |
|
10,754 |
|
10,199 |
|
19,394 |
|
21,034 |
|
|||||||||
Revenue per day filled (q) |
$ |
1,835 |
|
$ |
1,676 |
|
$ |
1,783 |
|
$ |
1,807 |
|
$ |
1,625 |
|
(a) |
Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as net (loss) income attributable to common shareholders before interest expense, income tax expense (benefit), depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, other expense (income), net, equity compensation, applicant tracking system costs, and includes net income attributable to noncontrolling interest in subsidiary. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to net income attributable to common shareholders as an indicator of operating performance. Management uses Adjusted EBITDA for planning purposes and as one performance measure in its incentive programs for certain members of its management team. Adjusted EBITDA, as defined, closely matches the operating measure typically used in the Company's credit facilities in calculating various ratios. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue. |
(b) |
Acquisition and integration-related costs include costs for prior acquisitions, costs incurred for potential transactions, and accretion and valuation adjustments related to the contingent consideration liability for the Mediscan acquisition. |
(c) |
Restructuring costs are primarily comprised of employee termination costs, lease-related exit costs, and reorganization costs as part of planned cost savings initiatives. |
(d) |
Legal settlements and fees include legal settlement charges as presented on the consolidated statements of operations as well as legal fees pertaining to non-operational legal matters which are included in selling, general and administrative expenses. For the three months ended |
(e) |
The three and six months ended |
(f) |
Loss on early extinguishment of debt relates to the write-off of debt issuance costs as a result of an optional reduction in borrowing capacity in the revolving credit facility exercised in the first quarter of 2019, and optional prepayments on the Company's term loan of |
(g) |
Applicant tracking system costs are related to the Company's project to replace its legacy system supporting its travel nurse staffing business. These costs are reported in selling, general and administrative expenses on the consolidated statement of operations and included in corporate overhead in segment data. |
(h) |
Adjusted EPS, a non-GAAP financial measure, is defined as net (loss) income attributable to common shareholders per diluted share before the diluted EPS impact of acquisition and integration-related costs, restructuring costs, legal settlements and fees, impairment charges, rebranding impairments and accelerated amortization, gain or loss on derivative, loss on early extinguishment of debt, gain or loss on sale of business, applicant tracking system costs, and nonrecurring income tax adjustments. Adjusted EPS should not be considered a measure of financial performance under GAAP. Management presents Adjusted EPS because it believes that Adjusted EPS is a useful supplement to its reported EPS as an indicator of operating performance. Management believes it provides a more useful comparison of the Company's underlying business performance from period to period and is more representative of the future earnings capacity of the Company. |
(i) |
Due to the net loss for the three months ended |
(j) |
Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. |
(k) |
Contribution income is defined as income or loss from operations before depreciation and amortization, acquisition and integration-related costs, restructuring costs, legal settlement charges, impairment charges, and corporate overhead. Contribution income is a financial measure used by management when assessing segment performance. |
(l) |
Corporate overhead includes unallocated executive leadership and other centralized corporate functional support costs such as finance, IT, legal, human resources, and marketing, as well as public company expenses and corporate-wide projects (initiatives). |
(m) |
Gross profit is defined as revenue from services less direct operating expenses. The Company's gross profit excludes allocated depreciation and amortization expense. Gross profit margin is calculated by dividing gross profit by revenue from services. |
(n) |
FTEs represent the average number of Nurse and |
(o) |
Average revenue per FTE per day is calculated by dividing the Nurse and |
(p) |
Days filled is calculated by dividing the total hours invoiced during the period, including an estimate for the impact of accrued revenue, by 8 hours. |
(q) |
Revenue per day filled is calculated by dividing revenue as reported by days filled for the period presented. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005970/en/
Executive Vice President and Chief Financial Officer
wburns@crosscountry.com
Source: